Biotech Earnings Preview: Arcturus and Rigel Set for Pivotal Q4 Reports

The upcoming fourth-quarter 2025 earnings reports for Arcturus Therapeutics and Rigel Pharmaceuticals represent a critical juncture for two distinct segments of the biotechnology sector: platform-driven mRNA innovation and targeted hematology-oncology commercialization. As the broader biotech market shifts its focus from speculative research and development toward tangible commercial execution and path-to-profitability metrics, these two companies serve as important bellwethers for investor sentiment in the mid-cap space. The results will provide a window into how specialized biotech firms are navigating the post-pandemic landscape and the increasingly competitive oncology market.

Arcturus Therapeutics is currently at the forefront of the next wave of mRNA technology. Unlike the conventional messenger RNA used by industry giants during the pandemic, Arcturus’s self-amplifying mRNA (sa-mRNA) platform is designed to allow for significantly lower dosing while potentially providing more robust and longer-lasting immune responses. The commercial launch of Kostaive in Japan, conducted in partnership with Meiji Seika Pharma and CSL, is the primary catalyst for the Q4 report. Investors are specifically looking for uptake data and royalty structures that could validate the sa-mRNA platform's commercial viability on a global scale. Beyond COVID-19, the progress of the company's pipeline—including ARCT-810 for Ornithine Transcarbamylase (OTC) deficiency and ARCT-032 for Cystic Fibrosis—will be scrutinized to determine if the platform can successfully pivot into the high-value rare disease therapeutics market.

“

The commercial launch of Kostaive in Japan, conducted in partnership with Meiji Seika Pharma and CSL, is the primary catalyst for the Q4 report.

Rigel Pharmaceuticals, conversely, is navigating the transition from a loss-making R&D firm to a profitable specialty pharmaceutical company. The focus for Rigel’s Q4 report is the continued growth trajectory of Tavalisse (fostamatinib) in the chronic immune thrombocytopenia (ITP) market and the market penetration of Rezlidhia (olutasidenib) in relapsed or refractory acute myeloid leukemia (AML). Rigel has demonstrated significant fiscal discipline over the past year, and the consensus estimate of a $0.01 earnings per share suggests the company is on the cusp of sustained profitability. This shift is vital for Rigel’s long-term strategy, as it would allow the company to self-fund its internal pipeline and potentially pursue strategic acquisitions without further dilutive equity raises, which have historically weighed on the stock's performance.